Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;35(12):1029-1033.
doi: 10.1051/medsci/2019204. Epub 2020 Jan 6.

[Rheumatology, the multitude of options]

[Article in French]
Jacques Morel  1 , Denis Mulleman  2
Affiliations
Review

[Rheumatology, the multitude of options]

[Article in French]
Jacques Morel et al. Med Sci (Paris). 2019 Dec.

Abstract
in English, French

The number of therapeutic antibodies available in rheumatology increases every year, mainly indicated in chronic inflammatory rheumatisms and other immune-mediated inflammatory diseases. The choice between all these monoclonal antibodies depends on their specificities, patients and diseases characteristics. Until now, there is no reliable biomarker, predictive of response for specialized medicine purpose. Today, therapeutic drug monitoring and anti-drug antibodies testing can help to better adapt the dose of the drug and to help in the decision to switch to another biological drug according to the activity of the inflammatory disease.

Title: Rhumatologie, la multitude des options.

Abstract: Le nombre d’anticorps (Ac) thérapeutiques disponibles en rhumatologie ne cesse de croître et concerne aussi bien les rhumatismes inflammatoires chroniques que les connectivites, les vascularites et, dans une moindre mesure, les pathologies osseuses et l’arthrose. Le choix d’un biomédicament repose aujourd’hui beaucoup sur les spécificités du médicament et des caractéristiques du patient. Il n’existe pas encore de véritables biomarqueurs prédictifs de réponse pour une médecine plus personnalisée. Le suivi sérique des Ac thérapeutiques et le dosage des anticorps anti-médicaments représentent un espoir pour adapter au mieux la posologie du médicament et décider d’un changement de traitement en fonction de l’activité de la maladie inflammatoire chronique.

PubMed Disclaimer

References

    1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011 ; 365: 2205–2219.
    1. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 ; 344: 1105–1110.
    1. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017 ; 389: 2328–2337.
    1. Stohl W.. Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol 2013 ; 9: 705–720.
    1. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 2015 ; 27: 127–133.

Substances